Page last updated: 2024-11-13

ethyl biscoumacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethyl Biscoumacetate: A coumarin that is used as an anticoagulant. It has actions similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Boeagenus[no description available]Gesneriaceae[no description available]

Cross-References

ID SourceID
PubMed CID54685524
CHEMBL ID81697
CHEMBL ID2106261
CHEBI ID135659
SCHEMBL ID42830
SCHEMBL ID1650108
MeSH IDM0007891

Synonyms (85)

Synonym
biscumacetato de etilo
3,3'-carbaethoxymethylen-bis-(4-oxy-cumarin)
08kl644731 ,
unii-08kl644731
ethylis biscoumacetas
ethyl biscoumacetate [inn:ban:nf]
biscoumacetate d'ethyle
2h-1-benzopyran-3-acetic acid, ethyl ester
3,3'-(carboxymethylene)bis(4-hydroxycoumarin) ethyl ester
boea
ethyl biscoumacetate
tromexan
trombarin
548-00-5
mls002607968 ,
ethyl biscumacetate
b. o. e. a.
ethyl ester of 3,3'-carboxymethylenebis(4-hydroxycoumarin)
pelentan
nsc36366
bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetic acid ethyl ester
neodicumarinum
ethyl 4,3'-acetate
neodikumarin
neodicoumarol
ethyldicoumarol acetate
bis-(4-hydroxy-3-coumarinyl)ethyl acetate
dicumacyl
neodicoumarin
nsc-36366
bis(4-hydroxy-3-coumarin)acetic acid ethyl ester
neodicumarol
ethyl bis(4-hydroxycoumarinyl)acetate
trombolysan
ethyl bis(4-hydroxy-3-coumarinyl)acetate
tromexan ethyl acetate
bis-3,3'-(4-hydroxycumarinyl)acetic acid ethyl ester
trombil
bis(hydroxycoumarin)acetic acid ethyl ester
wln: t66 bovj eq dyvo2&- dt66 bovj eq
einecs 208-940-5
ethyl 4,4'-dihydroxydicoumarinyl-3,3'-acetate
ethylis biscoumacetas [inn-latin]
ethyl bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)acetate
biscumacetato de etilo [inn-spanish]
acetic acid, bis(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)-, ethyl ester
aethylis biscumacetas
2h-1-benzopyran-3-acetic acid, 4-hydroxy-alpha-(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)-2-oxo-, ethyl ester
aethylum biscumaceticum
biscoumacetate d'ethyle [inn-french]
3,3'-carbaethoxymethylen-bis-(4-oxy-cumarin) [german]
nsc 36366
ethyldicoumarol
aethyli biscumacetas
stabilene
D07131
ethyl biscoumacetate (inn)
ethyl 2,2-bis(4-hydroxy-2-oxo-chromen-3-yl)acetate
CHEBI:135659
smr001526726
DB08794
bdbm35538
chembl81697 ,
FT-0668173
CHEMBL2106261
AKOS015995623
ethyl biscoumacetate [mart.]
ethyl biscoumacetate [who-dd]
ethyl biscoumacetate [mi]
ethyl biscoumacetate [inn]
SCHEMBL42830
dtxsid3057771 ,
cas-548-00-5
dtxcid4031560
NCGC00253742-01
tox21_113859
SCHEMBL1650108
ethyl bis(4-hydroxy-2-oxo-2h-chromen-3-yl)acetate #
2h-1-benzopyran-3-acetic acid, 4-hydroxy-.alpha.-(4-hydroxy-2-oxo-2h-1-benzopyran-3-yl)-2-oxo-, ethyl ester
JCLHQFUTFHUXNN-UHFFFAOYSA-N
bis(4-hydroxycoumarin)acetic acid ethyl ester
Q426269
di(4-oxi-cymarinyl-3);pelentan;trombarin;trombil;trombolysan
BCP26331
ethyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacodynamic parameters were measured for 96 hours."( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate].
Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G,
)
0.37

Bioavailability

ExcerptReferenceRelevance
" The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question."( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate].
Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G,
)
0.66

Dosage Studied

ExcerptRelevanceReference
" The blood was obtained from animals after single and multiple dosing of drugs."( Phytomenadione improves red cell deformability in laboratory animals.
Jakovljević, V; Sabo, A; Stanulović, M, 1992
)
0.28
" The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question."( [Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate].
Chanteclair, G; Copie, X; de Lauture, D; Letrait, M; Olive, G; Paltiat, MH; Pello, JY; Pinquier, JL; Rey, E; Strauch, G,
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency38.90180.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency23.91453.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency28.17960.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency0.29850.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.07330.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency34.67130.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.71010.001530.607315,848.9004AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency23.71010.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency3.09010.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency7.49720.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.44810.023723.228263.5986AID743223
thyroid stimulating hormone receptorHomo sapiens (human)Potency37.57800.001628.015177.1139AID1259385
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.01220.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency3.09010.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.09010.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NADHomo sapiens (human)IC50 (µMol)11.77700.00260.80763.4000AID1799313
Protease Human immunodeficiency virus 1IC50 (µMol)100.00000.00010.22487.3200AID162196
Integrase Human immunodeficiency virus 1IC50 (µMol)100.00000.00051.544310.0000AID93531; AID93543
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
fibroblast growth factor 22 isoform 1 precursorHomo sapiens (human)AbsAC1_uM5.00001.74007.917514.9200AID687022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein polyubiquitinationNADHomo sapiens (human)
response to ischemiaNADHomo sapiens (human)
NADH oxidationNADHomo sapiens (human)
ubiquinone metabolic processNADHomo sapiens (human)
xenobiotic metabolic processNADHomo sapiens (human)
nitric oxide biosynthetic processNADHomo sapiens (human)
response to oxidative stressNADHomo sapiens (human)
synaptic transmission, cholinergicNADHomo sapiens (human)
response to nutrientNADHomo sapiens (human)
response to toxic substanceNADHomo sapiens (human)
response to hormoneNADHomo sapiens (human)
response to carbohydrateNADHomo sapiens (human)
response to amineNADHomo sapiens (human)
removal of superoxide radicalsNADHomo sapiens (human)
protein catabolic processNADHomo sapiens (human)
response to estradiolNADHomo sapiens (human)
response to lipopolysaccharideNADHomo sapiens (human)
response to testosteroneNADHomo sapiens (human)
cellular response to oxidative stressNADHomo sapiens (human)
negative regulation of protein catabolic processNADHomo sapiens (human)
vitamin E metabolic processNADHomo sapiens (human)
vitamin K metabolic processNADHomo sapiens (human)
negative regulation of apoptotic processNADHomo sapiens (human)
response to alkaloidNADHomo sapiens (human)
positive regulation of neuron apoptotic processNADHomo sapiens (human)
innate immune responseNADHomo sapiens (human)
cell redox homeostasisNADHomo sapiens (human)
response to ethanolNADHomo sapiens (human)
response to electrical stimulusNADHomo sapiens (human)
cellular response to hydrogen peroxideNADHomo sapiens (human)
NADPH oxidationNADHomo sapiens (human)
cellular response to metal ionNADHomo sapiens (human)
negative regulation of ferroptosisNADHomo sapiens (human)
response to tetrachloromethaneNADHomo sapiens (human)
response to L-glutamineNADHomo sapiens (human)
response to hydrogen sulfideNADHomo sapiens (human)
response to flavonoidNADHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA bindingNADHomo sapiens (human)
cytochrome-b5 reductase activity, acting on NAD(P)HNADHomo sapiens (human)
superoxide dismutase activityNADHomo sapiens (human)
protein bindingNADHomo sapiens (human)
NADPH dehydrogenase (quinone) activityNADHomo sapiens (human)
identical protein bindingNADHomo sapiens (human)
NADH:ubiquinone reductase (non-electrogenic) activityNADHomo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityNADHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusNADHomo sapiens (human)
cytoplasmNADHomo sapiens (human)
cytosolNADHomo sapiens (human)
dendriteNADHomo sapiens (human)
neuronal cell bodyNADHomo sapiens (human)
synapseNADHomo sapiens (human)
cytosolNADHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1799313Inhibition of NQO1 (With 2 uM BSA) from Article 10.1021/jm9011609: \\Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).\\2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).
AID93531Inhibitory activity against HIV-1 integrase1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
AID93543Inhibitory activity against HIV-1 integrase1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
AID162196Inhibitory activity against HIV-1 protease1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (363)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990342 (94.21)18.7374
1990's8 (2.20)18.2507
2000's3 (0.83)29.6817
2010's4 (1.10)24.3611
2020's6 (1.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.01 (24.57)
Research Supply Index6.01 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.74%)5.53%
Reviews6 (1.49%)6.00%
Case Studies23 (5.69%)4.05%
Observational0 (0.00%)0.25%
Other372 (92.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]